← Back to the library
DepressionJanuary 1, 2024 · 11 min read

Agomelatine: The Antidepressant Not Available in America and Why

What is Agomelatine?

Agomelatine: The Antidepressant Not Available in America and Why

What is Agomelatine?

Agomelatine, also known by the brand names Valdoxan and Melitor, is a melatonergic antidepressant. It has a chemical name of N-[2-(7-methoxy-1-naphthalenyl)-ethyl] acetamide.

Agomelatine belongs to a class of drugs called melatonin receptor agonists - specifically, it is an agonist at MT1 and MT2 receptors in the brain. This means that agomelatine stimulates and activates these receptors. The natural hormone melatonin also acts as an agonist at these receptors, which are involved in regulating circadian rhythms.

Unlike most other antidepressants, Agomelatine has a novel action as it is both a melatonin receptor agonist and a serotonin 5-HT2C receptor antagonist. The combination of these properties is believed to contribute to its antidepressant effects.

History of Agomelatine

Agomelatine was developed in the 1990s by pharmaceutical companies Servier and Novartis. It was first marketed for the treatment of major depressive disorder in 2009 in Europe under the brand names Valdoxan and Thymanax.

In 2006, the European Medicines Agency (EMA) approved agomelatine for the treatment of major depressive episodes in adults. However, in 2009 the United States Food and Drug Administration (FDA) did not approve agomelatine, citing concerns about liver toxicity from clinical trials data. The FDA requested additional safety data from longer term studies before reconsidering approval in the US market.

Novartis discontinued partnership with Servier to market agomelatine in the US in 2011 after the FDA again did not approve the drug following review of additional safety data. Despite lack of FDA approval, Servier continued seeking approval for agomelatine for the US market over the next decade, providing further safety studies and evidence to the FDA.

As of 2022, agomelatine still does not have FDA approval and is not available for prescription in the United States. It remains approved and marketed for depression treatment in Europe and other countries worldwide.

Mechanism of Action

Agomelatine is an antidepressant that works differently than most other antidepressants. It has a dual mechanism of action that involves modulation of both serotonin and melatonin pathways in the brain.

Unlike SSRIs which act solely on serotonin, agomelatine is an agonist at MT1 and MT2 receptors. This means it binds to and activates melatonin receptors in the brain. Activation of MT1 and MT2 receptors helps resynchronize circadian rhythms and the sleep/wake cycle, which is often disrupted in depression.

In addition, agomelatine is an antagonist at 5-HT2C receptors. By blocking 5-HT2C receptors, it promotes the release of dopamine and norepinephrine in the frontal cortex. This helps lift mood and alleviate symptoms of depression. The combination of effects on melatonin and serotonin pathways leads to its antidepressant properties.

By working on both serotonin and melatonin, agomelatine provides a novel dual-action approach to treating depression. Studies show it is effective at reducing depressive symptoms while also helping regulate sleep.

Evidence for Use

Agomelatine has shown efficacy in treating major depressive disorder (MDD) in adults. Several randomized controlled trials have demonstrated that agomelatine can reduce symptoms of depression compared to placebo.

A 2010 meta-analysis compiled data from 12 clinical trials involving over 4000 patients and found that agomelatine was significantly more effective than placebo at improving depressive symptoms.[1] One key 8-week study showed agomelatine 25-50mg led to remission in 49% of patients, compared to just 35% on placebo.[2]

Additional studies show potential benefits in some patients who have failed other antidepressant therapies. One trial found that agomelatine demonstrated efficacy in MDD patients who had not responded adequately to selective serotonin reuptake inhibitors (SSRIs) or serotonin–norepinephrine reuptake inhibitors (SNRIs).[3]

There is some evidence that agomelatine may help with sleep regulation in depression. Some studies show improvements in sleep quality and daytime sleepiness.[4] However, more research is still needed.

While approved in Europe for MDD, agomelatine does not yet have FDA approval for use in the United States. More extensive clinical trials would be needed to meet US regulatory standards. But the current evidence demonstrates agomelatine can be an effective option for treating major depression in adults.

Benefits vs. Other Antidepressants

Agomelatine differs from many other commonly prescribed antidepressants in its mechanisms of action and side effect profile. Here's how it compares to other major classes of antidepressants:

-SSRIs (Selective Serotonin Reuptake Inhibitors) - Agomelatine does not act as a serotonin reuptake inhibitor like SSRIs such as Prozac, Zoloft, and Lexapro. Therefore, it does not carry the same side effects associated with increasing serotonin levels, such as nausea, diarrhea, insomnia, and sexual dysfunction. However, it may not be as effective for some patients who respond well to SSRIs.

-SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) - Similar to SSRIs, Agomelatine does not block the reuptake of serotonin or norepinephrine like SNRIs such as Cymbalta, Effexor, and Pristiq. It avoids the side effects of SNRIs like increased blood pressure but may not work as well for some patients.

-Tricyclic Antidepressants - Agomelatine has a much more favorable side effect profile than older tricyclic antidepressants like Elavil and Tofranil. It does not cause anticholinergic side effects like dry mouth, constipation, blurred vision or cardiac side effects. However, tricyclics could be more potent for some severe depression.

-MAOIs (Monoamine Oxidase Inhibitors) - Agomelatine does not inhibit monoamine oxidase enzymes like MAOIs such as Nardil and Parnate. Therefore, it does not require restrictive dietary restrictions or have concerning drug-drug interactions like MAOIs. However, MAOIs can be very effective antidepressants when prescribed appropriately.

-Other Atypical Antidepressants - Compared to other atypical antidepressants like Remeron (Mirtazapine) and Wellbutrin (Bupropion), Agomelatine has a relatively low risk of side effects and interactions. However, these alternatives may work better for some patients.

In summary, Agomelatine offers a mechanism of action and tolerability profile distinct from many other antidepressant drug classes. While it may not work for every patient, it provides an option for those intolerant to or not improving on other medications. More comparative research is still needed.

Dosing

The recommended dose of agomelatine for treating depression is 25-50 mg taken orally once daily at bedtime. Agomelatine is available in tablet form in doses of 25 mg and 50 mg.

It is recommended to start with a dose of 25 mg once daily for the first two weeks. After two weeks, the dose can be increased to 50 mg once daily if needed, as the higher dose has been shown to provide additional efficacy. The maximum recommended dose is 50 mg per day.

Agomelatine should be taken at bedtime because it can cause drowsiness. Taking it at night may help promote sleep, which is beneficial for patients with depression who often have insomnia.

If a dose is missed, the next dose should be taken the following day at the usual time. The missed dose should not be taken together with the next scheduled dose.

Elderly patients over 65 may be more sensitive to the effects of agomelatine and may need a lower starting dose of 25 mg per day. Caution is advised in patients with severe renal impairment, for whom dose reduction to 25 mg once daily is recommended.

Agomelatine is not approved for use in children or adolescents under 18 years of age. More studies are needed to establish safety and efficacy in the pediatric population.

Overall, agomelatine has a simple once-daily dosing regimen, taken at bedtime, with 25 mg being the starting dose and 50 mg being the maximum dose for most adult patients. Careful adherence to the recommended dosing guidelines can help optimize results.

Side Effects and Risks

Agomelatine has a favorable side effect profile compared to other antidepressants. The most common side effects include:

- Headache

- Nausea

- Dizziness

- Diarrhea

- Fatigue

- Abdominal pain

- Increased liver enzymes (ALT/AST)

In rare cases, agomelatine can cause hepatitis and liver injury. Liver function tests must be monitored carefully, especially at the beginning of treatment. Use with caution in patients with liver disease.

Agomelatine should not be used in combination with potent CYP1A2 inhibitors like fluvoxamine and ciprofloxacin, as this increases blood levels of agomelatine substantially.

Other contraindications include:

- Severe kidney impairment

- Known hypersensitivity to agomelatine or excipients

- Pregnancy and breastfeeding

Agomelatine carries a black box warning about increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (under 25 years old). Patients starting agomelatine should be monitored closely for worsening mood, agitation, and suicidal ideation.

Discontinuation syndrome has occurred in some patients stopping agomelatine abruptly. The medication should be gradually tapered when discontinuing.

Overall, agomelatine has less drug interactions and side effects compared to older classes of antidepressants like SSRIs and SNRIs. But regular monitoring, especially of liver enzymes, is still required with its use.

Positives

Agomelatine has several benefits and advantages compared to other antidepressants:

- It has a novel mechanism of action that targets melatonin receptors, providing antidepressant effects through regulation of circadian rhythms. This different approach may help patients who haven't responded to other antidepressants.

- Studies show it is effective for treating major depressive disorder, especially severe depression. It performs similarly to other common antidepressants in clinical trials.

- It has very low potential for drug interactions compared to SSRIs, SNRIs, and other antidepressants that interact with liver enzymes. This makes it safer to combine with other medications a patient may be taking.

- The side effect profile is relatively mild compared to older classes of antidepressants. There are lower rates of weight gain, sleep disturbances, and sexual side effects.

- It poses a low risk of discontinuation symptoms if the medication needs to be stopped. This makes it easier for patients to taper off the drug.

- It can help normalize sleep cycles in depressed patients with insomnia or other circadian rhythm disruptions. Restoring healthy sleep may provide added mood benefits.

- Some research indicates it may have neuroprotective and neurogenic effects in animal studies, suggesting potential to protect neurons and stimulate neurogenesis. However more studies are needed to confirm this in humans.

- It may have a faster onset of therapeutic action compared to SSRIs. Patients could see improvement in depression within 2 weeks rather than 4-6 weeks.

Overall, agomelatine provides a novel antidepressant option with a favorable side effect profile and some unique benefits compared to older drug classes. For certain patients, it may be an advantageous alternative.

Negatives

Agomelatine may have some disadvantages compared to other antidepressants. A few key downsides to consider:

- Not approved for use in the United States - Agomelatine is not approved by the FDA for use in the US due to concerns about liver toxicity. This limits access for patients in the US.

- Liver toxicity - There is a risk of elevated liver enzymes and potential liver damage, especially during the first few months of treatment. Regular liver function monitoring is required.

- Fewer drug interactions studied - Compared to older antidepressants, there has been less research into drug-drug interactions with agomelatine. Caution is needed when combining with other medications.

- Limited long-term safety data - Agomelatine is a relatively newer drug so the long-term effects beyond 1 year are less well studied. More data is needed on the safety with prolonged use.

- May be less effective than alternatives - Some analyses suggest agomelatine may be slightly less effective for depression than other available antidepressants. The comparative efficacy has not been definitively established.

- Lack of generic - Currently there is no generic version of agomelatine available. The brand name Valdoxan can be quite expensive and may not be covered by some insurance plans.

- Twice daily dosing - Unlike some other antidepressants, agomelatine needs to be taken twice per day. This may make it harder for some patients to adhere to the dosing schedule.

- Requires gradual discontinuation - Because of the risk of withdrawal effects, agomelatine has to be gradually tapered off over a couple weeks when discontinuing. This makes stopping the medication more difficult.

- More potential interactions with contraceptives - Agomelatine appears to have more interactions with oral contraceptives than some other antidepressants. The contraceptive effects may be reduced.

- May not be suitable for severe depression - Most evidence is around treatment of mild to moderate major depressive disorder. Agomelatine may be less optimal for patients with more severe depression.

Conclusion

Agomelatine is a novel antidepressant that functions as an MT1 and MT2 agonist and 5-HT2C antagonist. While promising research demonstrated its efficacy and favorable side effect profile compared to SSRIs and SNRIs, agomelatine has not been approved for use in the United States.

Some key reasons why agomelatine has not been approved in the US include:

- Concerns about potential liver toxicity. Several cases of elevated liver enzymes were reported in clinical trials. While serious hepatic events are rare, the risks were viewed as outweighing the benefits.

- Insufficient evidence of efficacy. While some studies showed agomelatine was more effective than placebo, the FDA determined the clinical trial data was not robust enough to demonstrate substantial efficacy above already approved antidepressants.

- Questions about abuse potential. Agomelatine acts on melatonin receptors which regulate sleep-wake cycles. There were concerns it may disrupt normal sleep architecture.

- Lack of long-term safety data. As agomelatine is a newer drug, there is limited data on its long-term safety with prolonged use.

Despite its innovation, agomelatine needs further evidence to definitively establish its favorable risk-benefit profile. More research could eventually support approval in the US, but for now it remains an experimental antidepressant.

Explore agomelatine: a distinct antidepressant unapproved in the US, its dosing, side effects, and SSRIs comparison.

By Birk Gundersen RN, BSN.

Words worth knowing

Insomnia

A sleep disorder involving persistent difficulty falling asleep, staying asleep, or getting restorative sleep.

Black box warning

The FDA’s most prominent medication warning, used when a medicine carries a serious or potentially life-threatening risk.

Educational content—not medical advice.Find support resources →